Skip to main content
NATURECELL CO.,LTD. logo

NATURECELL CO.,LTD. — Investor Relations & Filings

Ticker · 007390 ISIN · KR7007390008 KO Manufacturing
Open in API
Filings indexed 273 across all filing types
Latest filing 2023-02-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 007390

About NATURECELL CO.,LTD.

http://en.naturecell.co.kr/

NATURECELL CO.,LTD. is a diversified company operating across the food, beverage, cosmetics, and biotechnology sectors. The company manufactures and sells a range of products including canned goods, health functional foods, and fruit juices. In addition to its consumer goods, NATURECELL has a significant focus on its high-tech biotechnology division, which is dedicated to stem cell research and development. This division conducts clinical trials for potential therapeutic applications, with a noted emphasis on treatments for degenerative diseases such as Alzheimer's.

Recent filings

Filing Released Lang Actions
최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Nature Cell) announcing a change in its largest shareholder. It details the 'before' and 'after' shareholding structure, the reason for the change, and provides comprehensive information about the new largest shareholder (Biostar Group). This type of disclosure is a standard regulatory requirement for public companies to report significant changes in ownership structure, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for individual insider trades) or 'Major Shareholding Notification' (which is typically for external investors crossing thresholds).
2023-02-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by a major shareholder (Naturecell) and its special related parties, including specific transaction dates, methods (market sales), and share counts. This falls under the category of Major Shareholding Notification.
2023-01-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the change in share ownership by a major shareholder (Rbio Co., Ltd.) in Naturecell. This type of filing is a standard regulatory disclosure for changes in significant shareholdings or insider holdings, which falls under the 'Major Shareholding Notification' category.
2023-01-27 Korean
[기재정정]투자판단관련주요경영사항(동종지방유래 줄기세포를 이용한 퇴행성관절염 줄기세포치료제(아조스템) 개발을 위한 기술도입계약 해지)
M&A Activity Classification · 100% confidence The document is a regulatory filing from NatureCell regarding a 'Correction Report' (정정신고) for a previously disclosed 'Major Management Matter' (투자판단 관련 주요경영사항). It details the termination of a technology licensing agreement for a stem cell treatment (Azostem) and provides updated information on the repayment of the contract deposit and collateral arrangements. Since this is a formal regulatory disclosure of a material business event that does not fit into specific categories like M&A or financial reports, it is classified as a general regulatory filing.
2023-01-03 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory notice of the meeting preparation. Given the nature of the announcement as a regulatory filing regarding corporate governance procedures, it fits best under the RNS category.
2022-12-15 Korean
투자판단관련주요경영사항(동종지방유래 줄기세포를 이용한 퇴행성관절염 줄기세포치료제(아조스템) 개발을 위한 기술도입계약 해지)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Nature Cell regarding the termination of a technology licensing agreement for a stem cell treatment (JointStem). It is a specific corporate announcement detailing a material business decision (contract termination) and its financial implications (return of 8 billion KRW). Since it does not fit into specific categories like M&A (which usually involves corporate combinations) or legal proceedings (which usually involve litigation), and it is a formal regulatory disclosure of a material event, it falls under the general regulatory filing category.
2022-12-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.